Press releases

Oxford BioMedica Plc Management and Board Changes

--Oxford BioMedica Appoints Alex Lewis as Director of Corporate Activities and Strategy--

Oxford, UK – 24 May 2011: Oxford BioMedica (LSE: OXB), a leading gene therapy company, today announces that Dr Alex Lewis has been appointed as Director of Corporate Activities and Strategy and a member of the senior management team with immediate effect.  As a result, he will step down from the Board of Oxford BioMedica.

Alex is an experienced consultant to the pharmaceutical and biotech industry with a background of over 24 years in medical research and drug development.  Alex was appointed to Oxford BioMedica’s Board in April 2008 and was also Director of Transactions and Due Diligence at The Datamonitor Group until June 2009 when he became Director of Lewis Healthcare Consultants.  Prior to this, he was Head of the Partnering and Due Diligence practice of Wood Mackenzie research consultants.  Alex has also been involved in the provision of expert reports and technical advice for the initial public offerings and fundraising activities for biotech companies based in the US and Europe.

John Dawson, Chief Executive Officer of Oxford BioMedica, said: “Alex is an expert addition to the senior management team as we continue to build Oxford BioMedica as a successful biopharmaceutical company founded on the development and commercialisation of products derived from innovative technology platforms.  Alex’s knowledge and advice will also be instrumental in evaluating other value-enhancing opportunities to grow the business.”

In place of Dr Alex Lewis, Dr Paul Blake will become Chairman of Oxford BioMedica’s remuneration committee and Dr Andrew Heath, Senior Independent Director and Deputy Chairman of Oxford BioMedica, will join the Company’s remuneration committee. 


Notes to editors

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at

For further information please contact

Oxford BioMedica plc

John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Sarah MacLeod, Head of Communications
Tel: +44 (0)1865 783 000

Financial and corporate communications enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton
Tel: +44 (0)20 3709 5700